H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on Bionomics (BNOX – Research Report) today. The company’s shares opened today at $4.93.
Pantginis covers the Healthcare sector, focusing on stocks such as Clene, Rigel, and Actinium Pharmaceuticals. According to TipRanks, Pantginis has an average return of -10.0% and a 37.07% success rate on recommended stocks.
Bionomics has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.
See the top stocks recommended by analysts >>
BNOX market cap is currently $26.1M and has a P/E ratio of -2.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company’s reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
Read More on BNOX:
